0001209191-20-045144.txt : 20200805
0001209191-20-045144.hdr.sgml : 20200805
20200805165109
ACCESSION NUMBER: 0001209191-20-045144
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200803
FILED AS OF DATE: 20200805
DATE AS OF CHANGE: 20200805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandercock Colin
CENTRAL INDEX KEY: 0001724870
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 201078305
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-03
0
0001645460
Cue Biopharma, Inc.
CUE
0001724870
Sandercock Colin
21 ERIE STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP, General Counsel and Sec
Common Stock
2020-08-03
4
M
0
6425
7.50
A
23550
D
Common Stock
2020-08-03
4
S
0
6425
20.00
D
17125
D
Common Stock
2020-08-04
4
M
0
201
7.50
A
17326
D
Common Stock
2020-08-04
4
S
0
201
20.05
D
17125
D
Stock Option (right to buy)
7.50
2020-08-03
4
M
0
6425
0.00
D
2024-12-27
Common Stock
6425
143575
D
Stock Option (right to buy)
7.50
2020-08-04
4
M
0
201
0.00
D
2024-12-27
Common Stock
201
143374
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018.
/s/ Colin Sandercock by Mark Busch, as attorney-in-fact
2020-08-05